Liquid chromatography-mass spectrometry method for the quantification of an anti-sclerostin monoclonal antibody in cynomolgus monkey serum  

作　　者：Yuxiong Gao Zhendong Chen Changyong Yang Dafang Zhong 

机构地区：[1]State Key Laboratory of Drug Research,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai,201210,China [2]University of Chinese Academy of Sciences,Beijing,100049,China [3]Preclinical Department,Hengrui Medicine Co.,Ltd.,Lianyungang,Jiangsu Province,222047,China

出　　处：《Journal of Pharmaceutical Analysis》2021年第4期472-479,共8页药物分析学报（英文版）

基　　金：supported by the National Natural Science Foundation of China(Grant No.81521005);the National Key Research Project of the Chinese Academy of Sciences(Grant No.XDA12050306)。

摘　　要：Liquid chromatography tandem mass spectrometry(LC-MS/MS)has gradually become a promising alternative to ligand binding assay for the bioanalysis of biotherapeutic molecules,due to its rapid method development and high accuracy.In this study,we established a new LC-MS/MS method for the determination of the anti-sclerostin monoclonal antibody(SHR-1222)in cynomolgus monkey serum,and compared it to a previous electrochemiluminescence method.The antibody was quantified by detecting the surrogate peptide obtained by trypsin digestion.The surrogate peptide was carefully selected by investigating its uniqueness,stability and MS response.The quantitative range of the proposed method was 2.00-500μg/mL,and this verified method was successfully applied to the toxicokinetic assessment of SHR-1222 in cynomolgus monkey serum.It was found that the concentrations of SHR-1222 in cynomolgus monkeys displayed an excellent agreement between the LC-MS/MS and electrochemiluminescence methods(ratios of drug exposure,0.8-1.0).Notably,two monkeys in the60 mg/kg dose group had abnormal profiles with a low detection value of SHR-1222 in their individual sample.Combining the high-level anti-drug antibodies(ADAs)in these samples and the consistent quantitative results of the two methods,we found that the decreased concentration of SHR-1222 was due to the accelerated clearance mediated by ADAs rather than the interference of ADAs to the detection platform.Taken together,we successfully developed an accurate,efficient and cost-effective LC-MS/MS method for the quantification of SHR-1222 in serum samples,which could serve as a powerful tool to improve the preclinical development of antibody drugs.

关 键 词：Anti-sclerostin monoclonal antibody (SHR-1222) LC-MS/MS Anti-drug antibody TOXICOKINETIC 

分 类 号：R969[医药卫生—药理学]